COPENHAGEN, Denmark - May 14, 2019 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2019 first quarter results on Wednesday, May 22, 2019.
The management of Bavarian Nordic will host a conference call at 2:00 pm CEST.
To join the Q&A session dial one of the following numbers and state the participant code 3096344: Denmark: +45 32 72 80 42, UK: +44 (0) 844 571 8892, USA: +1 631-510-7495.
Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations & Communications. Phone +45 61 77 47 43
U.S.: Graham Morrell, Paddock Circle Advisors (US), Tel: +1 781 686 9600
About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company focused on the development of innovative therapies against cancer and infectious diseases. Using our live virus vaccine platform technology, MVA-BN, we have created a diverse portfolio of proprietary and partnered product candidates intended to improve the health and quality of life for children and adults. We supply our MVA-BN non-replicating smallpox vaccine to the U.S. Strategic National Stockpile and other government stockpiles. The vaccine is approved in the European Union and in Canadaor follow us on Twitter @bavariannordic.
